NPPA to Revisit Price Controls on Coronary Stents

India’s National Pharmaceutical Pricing Authority said it will revisit the ceiling prices imposed earlier this year on coronary stents.

In a Nov. 9 memorandum, NPPA said this may happen as early as January 2018.

The authority also set price caps for knee implants this year. Average prices were slashed by up to 85 percent for coronary stents and 70 percent for knee implants.

NPPA issued the new memorandum after it received a request from at least one international medical device manufacturer — Abbott Healthcare — to withdraw its coronary stents from the market because of “commercial unviability.”